Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11465197 | 0.83 | MEN1 (0.49) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL29957449 | 0.82 | UNG (0.68) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL18432542 | 0.82 | UNG (0.68) | UNGTDP1HPGDTTR | |
| SCHEMBL1482839 | 0.82 | UNG (0.68) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL28167538 | 0.80 | KMT2A (0.46) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL5950219 | 0.80 | MEN1 (0.46) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL14435609 | 0.80 | MEN1 (0.46) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL4153267 | 0.80 | TDP1 (0.50) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL29838039 | 0.80 | TDP1 (0.50) | ALDH1A1MEN1KMT2AUNGCREBBP | |
| SCHEMBL3696065 | 0.78 | KMT2A (0.45) | ALDH1A1MEN1KMT2AUNGCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-1577314-B1 | Catalyst based on a transition metal complex for polymerization of olefins, and process for polymerization of olefins using the catalyst | TOSOH CORP (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-20060229470-A1 | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1210714-A4 | HIGH DENSITY NON-VOLATILE MEMORY DEVICE | UNIV (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1553078-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1466888-A1 | Calcium receptor-active arylalkyl amines | NPS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1275635-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1210714-A2 | HIGH DENSITY NON-VOLATILE MEMORY DEVICE | The Regents of the University of California (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1203761-A2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6313146-B1 | CAN BE USED FOR THERAPY OF DISEASES OR DISORDERS IN A PATIENT BY MODULATING ONE OR MORE INORGANIC ION RECEPTOR ACTIVITIES | NPS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6011068-A | CARBOCYCLIC-ALKYL SECONDARY AMINES | NPS PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-6001884-A | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5962314-A | CERTAIN CELLS IN THE BODY RESPOND NOT ONLY TO CHEMICAL SIGNALS, BUT ALSO TO IONS SUCH AS EXTRACELLULAR CALCIUM IONS (CA.SUP.2+). THE INVENTION RELATES TO NUCLEIC ACIDS ENCODING SUCH RECEPTORS AND CELLS CONTAINING SUCH NUCLEIC ACIDS. | NPS PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5858684-A | CONTACTING RECOMBINANT CELL WITH TEST COMPOUND WHICH IS NOT VERAPAMIL OR GALLOPAMIL, DETERMINING ABILITY OF COMPOUND TO AFFECT ACTIVITIES OF INORGANIC ION RECEPTOR; DETERMINATION OF AGONIST AND ANTAGONIST DRUGS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5763569-A | POLYPEPTIDES AS CALCIUM RECEPTORS TO GENERATE ANTIBODIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 1998-06-09 | — | — | US | disclosed |
| US-5688938-A | Calcium receptor-active molecules | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0787122-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0724561-A1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996012697-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995011221-A1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMACEUTICALS, INC. (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229470-A1 | Calcium receptor-active molecules | CASR, CALCR, ORAI1 | ALDH1A1 4730/4885MEN1 3324/4885KMT2A 4522/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | ALDH1A1 4730/4885MEN1 3324/4885KMT2A 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.